Adam M. Veness

CIK: 0001778623

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)5 (45.5%)

Position reduction

Option Exercises (M)4 (36.4%)

Derivative conversions

Awards (A)2 (18.2%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

DNTH

Dianthus Therapeutics, Inc. /DE/

Officer

Discretionary Trading P&L

Holdings

Transaction History (11 total)

DNTH
Dianthus Therapeutics, Inc. /DE/
Aug 13, 2026
Exercise(M)
Direct
15K shares at avg. $18.17$273K
DNTH
Dianthus Therapeutics, Inc. /DE/
Aug 10, 2026
Exercise(M)
Direct
16.2K shares at avg. $17.88$289K
DNTH
Dianthus Therapeutics, Inc. /DE/
Aug 10, 2026
Sale(S)
Direct
16.2K shares at avg. $110.38$1.8M
DNTH
Dianthus Therapeutics, Inc. /DE/
Aug 7, 2026
Sale(S)
Direct
3.2K shares at avg. $110.61$356K
DNTH
Dianthus Therapeutics, Inc. /DE/
Aug 7, 2026
Sale(S)
Direct
616 shares at avg. $111.18$68K
DNTH
Dianthus Therapeutics, Inc. /DE/
Aug 7, 2026
Exercise(M)
Direct
3.8K shares at avg. $17.88$69K
DNTH
Dianthus Therapeutics, Inc. /DE/
Jun 17, 2026
Exercise(M)
Direct
30K shares at avg. $17.88$536K
DNTH
Dianthus Therapeutics, Inc. /DE/
Jun 17, 2026
Sale(S)
Direct
16.8K shares at avg. $80.34$1.3M
DNTH
Dianthus Therapeutics, Inc. /DE/
Jun 17, 2026
Sale(S)
Direct
13.2K shares at avg. $81.38$1.1M
DNTH
Dianthus Therapeutics, Inc. /DE/
Feb 3, 2026
Award(A)
Stock Option (Right to Buy)
Direct
100K shares-
DNTH
Dianthus Therapeutics, Inc. /DE/
Feb 3, 2025
Award(A)
Stock Option (Right to Buy)
Direct
100K shares-

		Type	Shares	Price		Ownership
Aug 13, 2026	DNTH Dianthus Therapeutics, Inc. /DE/	Exercise(M)	15,000	$18.17	$272,550	Direct
Aug 10, 2026	DNTH Dianthus Therapeutics, Inc. /DE/	Exercise(M)	16,167	$17.88	$289,066	Direct
Aug 10, 2026	DNTH Dianthus Therapeutics, Inc. /DE/	Sale(S)	16,167	$110.38	$1,784,513	Direct
Aug 7, 2026	DNTH Dianthus Therapeutics, Inc. /DE/	Sale(S)	3,217	$110.61	$355,832	Direct
Aug 7, 2026	DNTH Dianthus Therapeutics, Inc. /DE/	Sale(S)	616	$111.18	$68,487	Direct
Aug 7, 2026	DNTH Dianthus Therapeutics, Inc. /DE/	Exercise(M)	3,833	$17.88	$68,534	Direct
Jun 17, 2026	DNTH Dianthus Therapeutics, Inc. /DE/	Exercise(M)	30,000	$17.88	$536,400	Direct
Jun 17, 2026	DNTH Dianthus Therapeutics, Inc. /DE/	Sale(S)	16,771	$80.34	$1,347,382	Direct
Jun 17, 2026	DNTH Dianthus Therapeutics, Inc. /DE/	Sale(S)	13,229	$81.38	$1,076,576	Direct
Feb 3, 2026	DNTH Dianthus Therapeutics, Inc. /DE/	Award(A) Stock Option (Right to Buy)	100,000	-	-	Direct
Feb 3, 2025	DNTH Dianthus Therapeutics, Inc. /DE/	Award(A) Stock Option (Right to Buy)	100,000	-	-	Direct

1-11 of 11 transactions

About Veness Adam M

Veness Adam M (SEC CIK 0001778623) files insider reports with the SEC as SVP, General Counsel and Sec. of Dianthus Therapeutics, Inc. /DE/ (DNTH).

Signal8 holds 5 ownership filings by Veness Adam M, all Form 4s, filed between Feb 4, 2025 and Aug 14, 2026. Those filings report 11 transactions, from Feb 3, 2025 to Aug 13, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Veness Adam M's filings is in NEW YORK, NY.

Recent filings by Veness Adam M

Aug 13, 2026: Option exercise of DNTH shares (Form 4, code M).
Aug 10, 2026: Option exercise of DNTH shares (Form 4, code M).
Aug 10, 2026: Open-market sale of DNTH shares (Form 4, code S).
Aug 7, 2026: Open-market sales of DNTH shares (2 lines, Form 4, code S).
Aug 7, 2026: Option exercise of DNTH shares (Form 4, code M).

Other insiders filing for Dianthus Therapeutics, Inc. /DE/ (DNTH)

CARR EDWARD, CHIEF ACCOUNTING OFFICER
Randhawa Simrat, EVP, Head of R&D
Read Simon, Director
McGeorge Anne, Director
Garcia Marino, CEO AND PRESIDENT
Savitz Ryan, EVP, CFO & CBO

How to read Form 4 transaction codes